JPWO2019136016A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019136016A5 JPWO2019136016A5 JP2020555742A JP2020555742A JPWO2019136016A5 JP WO2019136016 A5 JPWO2019136016 A5 JP WO2019136016A5 JP 2020555742 A JP2020555742 A JP 2020555742A JP 2020555742 A JP2020555742 A JP 2020555742A JP WO2019136016 A5 JPWO2019136016 A5 JP WO2019136016A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- leukemia
- cancer
- aspects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 45
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 208000032839 leukemia Diseases 0.000 description 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229910052805 deuterium Inorganic materials 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- -1 Y 1 Chemical compound 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 239000012824 ERK inhibitor Substances 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862612926P | 2018-01-02 | 2018-01-02 | |
| US62/612,926 | 2018-01-02 | ||
| PCT/US2018/068102 WO2019136016A1 (en) | 2018-01-02 | 2018-12-31 | Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021509414A JP2021509414A (ja) | 2021-03-25 |
| JPWO2019136016A5 true JPWO2019136016A5 (enExample) | 2022-01-17 |
| JP7357637B2 JP7357637B2 (ja) | 2023-10-06 |
Family
ID=67143955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555742A Active JP7357637B2 (ja) | 2018-01-02 | 2018-12-31 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの同位体置換体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210069356A1 (enExample) |
| EP (1) | EP3735243A4 (enExample) |
| JP (1) | JP7357637B2 (enExample) |
| KR (1) | KR20200105662A (enExample) |
| CN (1) | CN111542321A (enExample) |
| WO (1) | WO2019136016A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA50518A (fr) | 2017-05-31 | 2020-09-09 | Taiho Pharmaceutical Co Ltd | Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 |
| KR20220110494A (ko) | 2019-11-05 | 2022-08-08 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일) 메틸)-2,2-디플루오로아세트아미드를 사용한 조합 요법 |
| CN114728899B (zh) | 2019-11-13 | 2023-12-05 | 大鹏药品工业株式会社 | 新型三苯基化合物盐 |
| CN114761004A (zh) | 2019-12-06 | 2022-07-15 | 细胞基因公司 | 用于制备2-(4-氯苯基)-n-((2-(2，6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2，2-二氟乙酰胺的方法 |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| CN113149801A (zh) * | 2021-01-27 | 2021-07-23 | 南京工业大学 | 氘代多卤素芳香族化合物及其制备方法、有机中间体 |
| CN113125602A (zh) * | 2021-04-16 | 2021-07-16 | 山东铂源药业有限公司 | 一种哌柏西利中残留溶剂的检测方法 |
| AU2022297176A1 (en) | 2021-06-25 | 2024-01-04 | Korea Research Institute Of Chemical Technology | Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof |
| EP4680597A1 (en) * | 2023-03-13 | 2026-01-21 | The Johns Hopkins University | Nonsense mediated decay inhibitor compounds |
| WO2025250721A1 (en) * | 2024-05-30 | 2025-12-04 | Celgene Corporation | Arnt degrading compounds and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9695145B2 (en) * | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| HK1219896A1 (zh) * | 2013-04-02 | 2017-04-21 | 细胞基因公司 | 使用4-氨基-2-(2，6-二氧代-呱啶-3-基)-异吲哚啉-1，3-二酮治疗和控制中枢神经系统癌症的方法和组合物 |
| US20150196562A1 (en) * | 2014-01-15 | 2015-07-16 | Celgene Corporation | Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| TWI733734B (zh) * | 2016-01-08 | 2021-07-21 | 美商西建公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧六氫吡啶-3-基)-1-氧基異吲哚啉-5-基)甲基)-2,2-二氟乙醯胺之固體型式，及其醫藥組合物及用途 |
-
2018
- 2018-12-31 JP JP2020555742A patent/JP7357637B2/ja active Active
- 2018-12-31 KR KR1020207018913A patent/KR20200105662A/ko not_active Withdrawn
- 2018-12-31 CN CN201880085364.0A patent/CN111542321A/zh active Pending
- 2018-12-31 EP EP18898451.2A patent/EP3735243A4/en not_active Withdrawn
- 2018-12-31 WO PCT/US2018/068102 patent/WO2019136016A1/en not_active Ceased
- 2018-12-31 US US16/959,560 patent/US20210069356A1/en not_active Abandoned